Sanofi has paused recruitment in its international phase 3 trials of BTK inhibitor tolebrutinib for multiple sclerosis, although it says studies aimed at getting US approval are on track to ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...